DR. MELINDA SUE DUNLAP MD NPI 1609096668

NPI Details

DR. Melinda Sue Dunlap, MD is a hematology and oncology internal medicine in Tulsa, OK with 22 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Melinda Sue Dunlap, MD NPI is 1609096668. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF ARKANSAS COLLEGE OF MEDICINE
Graduation Year:2004

The provider's business location address is:

12697 E 51ST ST
TULSA, OK
ZIP 74146-236
Phone: (918) 505-3200
Fax: (918) 505-3253

The NPI 1609096668 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Uric acid level, blood (HCPCS:84550)
• Magnesium level (HCPCS:83735)
• Phosphate level (HCPCS:84100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, obinutuzumab, 10 mg (HCPCS:J9301)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml (HCPCS:A9579)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Unclassified drugs (HCPCS:J3490)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Ct scan of chest with contrast (HCPCS:71260)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Blood creatinine level (HCPCS:82565)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Collection of blood sample from implanted device (HCPCS:36591)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Red blood count, automated test (HCPCS:85045)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Mri scan of brain before and after contrast (HCPCS:70553)
• Drawing of blood for a medical problem (HCPCS:99195)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Urine microalbumin (protein) analysis (HCPCS:82044)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Declotting of central venous tube (HCPCS:36593)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)

The enumeration date for this NPI number is 5/1/2007 and was last updated on 5/8/2014.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: